1. Home
  2. ALLO vs MVIS Comparison

ALLO vs MVIS Comparison

Compare ALLO & MVIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • MVIS
  • Stock Information
  • Founded
  • ALLO 2017
  • MVIS 1993
  • Country
  • ALLO United States
  • MVIS United States
  • Employees
  • ALLO N/A
  • MVIS N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • MVIS Industrial Machinery/Components
  • Sector
  • ALLO Health Care
  • MVIS Technology
  • Exchange
  • ALLO Nasdaq
  • MVIS Nasdaq
  • Market Cap
  • ALLO 338.9M
  • MVIS 308.8M
  • IPO Year
  • ALLO 2018
  • MVIS 1996
  • Fundamental
  • Price
  • ALLO $1.44
  • MVIS $1.22
  • Analyst Decision
  • ALLO Strong Buy
  • MVIS Buy
  • Analyst Count
  • ALLO 10
  • MVIS 4
  • Target Price
  • ALLO $9.66
  • MVIS $2.67
  • AVG Volume (30 Days)
  • ALLO 3.3M
  • MVIS 5.0M
  • Earning Date
  • ALLO 05-12-2025
  • MVIS 03-26-2025
  • Dividend Yield
  • ALLO N/A
  • MVIS N/A
  • EPS Growth
  • ALLO N/A
  • MVIS N/A
  • EPS
  • ALLO N/A
  • MVIS N/A
  • Revenue
  • ALLO $22,000.00
  • MVIS $4,696,000.00
  • Revenue This Year
  • ALLO N/A
  • MVIS $486.46
  • Revenue Next Year
  • ALLO $8.30
  • MVIS $139.22
  • P/E Ratio
  • ALLO N/A
  • MVIS N/A
  • Revenue Growth
  • ALLO N/A
  • MVIS N/A
  • 52 Week Low
  • ALLO $1.30
  • MVIS $0.80
  • 52 Week High
  • ALLO $4.30
  • MVIS $1.95
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.16
  • MVIS 45.33
  • Support Level
  • ALLO $1.49
  • MVIS $1.15
  • Resistance Level
  • ALLO $1.69
  • MVIS $1.28
  • Average True Range (ATR)
  • ALLO 0.14
  • MVIS 0.13
  • MACD
  • ALLO -0.03
  • MVIS -0.01
  • Stochastic Oscillator
  • ALLO 17.50
  • MVIS 12.96

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About MVIS MicroVision Inc.

Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.

Share on Social Networks: